Altogether, our results demonstrate that treatment of MM cells with the EZH2 inhibitor EPZ-6438 leads to significant upregulation of membrane CD38 expression, both in HMCLs and primary MM cells. The gene discussed is CD38; the disease is Miyoshi myopathy.